Why I'm Not Worried About Novo Nordisk Stock

Novo Nordisk (NYSE: NVO) stock has been a trainwreck of late. In just the past 12 months, the Danish healthcare stock has lost around 60% of its value. Things have been going from bad to worse for the business. Its guidance hasn't been looking good, and investors are now also concerned about its long-term prospects and ability to compete alongside rival Eli Lilly. While Novo Nordisk does have an approved GLP-1 weight loss pill on the market, the concern is that its advantage won't last long once Eli Lilly ...